Cyclosporine

Kidney Transplantation

Volumn , Issue , 2008, Pages 234-258

  Russell, Neil K I ^a,b   Knight, Simon R ^c,d   Morris, Peter J ^e,f  

^a ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c Dept for Education and Employment   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882490878     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3343-1.50020-7     Document Type: Chapter

References (361)

1. Abraham MA, Thomas PP, John GT, et al. Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc 2003, 35:215-216.
2. Abramowicz D, Goldman M, De Pauw L, et al. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 1992, 54:433-437.
3. Abramowicz D, Rial MDC, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005, 16:2234-2240.
4. Adu D, Turney J, Michael J, et al. Hyperkalaemia in cyclosporin-treated renal allograft recipients. Lancet 1983, 2:370-372.
5. Ahuja SS, Shrivastav S, Danielpour D, et al. Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995, 60:718-723.
6. Allen RD, Hunnisett AG, Morris PJ Cyclosporin and magnesium. Lancet 1985, 1:1283-1284.
7. Allen RD, Michie CA, Murie JA, et al. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987, 164:137-142.
8. Anderson CB, Tyler JD, Sicard GA, et al. Pretreatment of renal allograft recipients with immunosuppression and donor-specific blood. Transplantation 1984, 38:664-668.
9. Anderson CB, Brennan DC A sanguine outlook: the role of donor-specific transfusion in renal transplantation and tolerance. Transplant Rev 1995, 9:49.
10. Andoh TF, Gardner MP, Bennett WM Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 1997, 64:1236-1240.
11. Andrieu JM, Even P, Venet A, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988, 47:181-198.
12. Andrus L, Lafferty KJ Inhibition of T-cell activity by cyclosporin A. Scand J Immunol 1981, 15:449-458.
13. Anonymous Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors: preliminary results of a European multicentre trial. Lancet 1982, 2:57-60.
14. Anonymous Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983, 2:986-989.
15. Anonymous A randomized clinical trial of cyclosporine in cadaveric renal transplantation: Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 1986, 314:1219-1225.
16. Anonymous European multicentre trial of cyclosporine in renal transplantation: 10-year follow-up. Transplant Proc 1993, 25:527-529. (1 Pt 1).
17. Anonymous A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996, 61:1029-1037.
18. Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation. N Engl J Med 1984, 310:527.
19. Bakker RC, Hollander AAMJ, Mallat MJK, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003, 64:1027-1034.
20. Bantle JP, Nath KA, Sutherland DE, et al. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med 1985, 145:505-508.
21. Beaman M, Parvin S, Veitch PS, et al. Convulsions associated with cyclosporin A in renal transplant recipients. BMJ (Clin Res Ed) 1985, 290:139-140.
22. Belzer FO, Kalayoglu M, Sollinger HW Donor-specific transfusion in living-unrelated renal donor-recipient combinations. Transplant Proc 1987, 19:1514-1515. (1 Pt 2).
23. Bennett WM Comparison of cyclosporine nephrotoxicity with amino-glycoside nephrotoxicity. Clin Nephrol 1986, 25(Suppl 1):S126-S129.
24. Benvenisty AI, Cohen D, Stegall MD, et al. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990, 49:321-327.
25. Bevan PC, Seaman M, Tolliday B, et al. ABO haemolytic anaemia in transplanted patients. Vox Sang 1985, 49:42.
26. Bird AB Cyclosporin A, lymphomata and Epstein-Barr virus. Cyclosporine A 1982, 307. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
27. Bird AG, McLachlan SM, Britton S Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981, 289:300-301.
28. Birsan T, Loinig C, Bodingbauer M, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation 2004, 78:1787-1791.
29. Bistrup C, Nielsen FT, Jeppesen UE, et al. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant 2001, 16:373-377.
30. Blackhall ML, Fassett RG, Sharman JE, et al. Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. Nephrol Dial Transplant 2005, 20:1970-1975.
31. Bloom IT, Bentley FR, Spain DA, et al. An experimental study of altered nitric oxide metabolism as a mechanism of cyclosporin-induced renal vasoconstriction. Br J Surg 1995, 82:195-198.
32. Bobadilla NA, Tapia E, Franco M, et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 1994, 46:773-779.
33. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976, 6:468-475.
34. Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977, 32:1017-1025.
35. Borel JF Cyclosporin-A-present experimental status. Transplant Proc 1981, 13:344-348. (1 Pt 1).
36. Borel JF The history of cyclosporin A and its significance. Cyclosporine A 1982, 5. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
37. Bouchta NB, Ghisdal L, Abramowicz D, et al. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation. Transplant Proc 2005, 37:1857-1860.
38. Bouwer HGA, Hinrichs DJ Cyclosporin effects on mitogen-induced T- and B-cell proliferation. Transplant Proc 1983, 15:2306.
39. Bracht C, Yan XW, LaRocca HP, et al. Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension. J Hypertens 1999, 17:357-363.
40. Bunjes D, Hardt C, Solbach W, et al. Studies on mechanism of action of cyclosporin A in the murine and human T-cell response in vitro. Cyclosporine A 1982, 261. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
41. Bunzedahl H, Bechstein W, Wonigeit K Effects of immunosuppression on renal allograft survival in immunized patients: a single center analysis. Transplant Proc 1986, 18:1067.
42. Burckhardt JJ, Guggenheim B Cyclosporin A: in vivo and in vitro suppression of rat T-lymphocyte function. Immunology 1979, 36:753-757.
43. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995, 269:F491-F499. (4 Pt 2).
44. Burdmann EA, Andoh TF, Yu L, et al. Cyclosporine nephrotoxicity. Semin Nephrol 2003, 23:465-476.
45. Busauschina A, Schnuelle P, van der Woude FJ Cyclosporine nephrotoxicity. Transplant Proc 2004, 36(2 Suppl):229S-233S.
46. Calne RY, White DJ Cyclosporin A-a powerful immunosuppressant in dogs. IRCSJ Med Sci 1977, 5:595.
47. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979, 2:1033-1036.
48. Calne RY, Rolles K, White DJ, et al. Cyclosporin-A in clinical organ grafting. Transplant Proc 1981, 13:349-358. (1 Pt 1).
49. Calne RY, White DJ The use of cyclosporin A in clinical organ grafting. Ann Surg 1982, 196:330-337.
50. Calne RY Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 1987, 2:506-507.
51. Cammisuli S The effect of cyclosporin A on cell interactions within the immune system. Cyclosporine A 1982, 243. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
52. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56:714-719.
53. Campistol JM, Sacks SH Mechanisms of nephrotoxicity. Transplantation 2000, 69(12 Suppl):S5-S10.
54. Canadian Multicentre Transplant Study Group A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983, 309:809-815.
55. Carbajal H, Soltero L, Rodriguez-Montalvo C, et al. Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation 2004, 77:1038-1040.
56. Carel JC, Schreiber RD, Falqui L, et al. Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma. Proc Natl Acad Sci U S A 1990, 87:1591-1595.
57. Cattaneo D, Perico N, Gaspari F, et al. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004, 36(2 Suppl):234S-239S.
58. Cattaneo D, Gotti E, Perico N, et al. Cyclosporine formulation and Kaposi's sarcoma after renal transplantation. Transplantation 2005, 80:743-748.
59. Cauduro RL, Costa C, Lhulier F, et al. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 2005, 19:470-474.
60. Chan P, Chapman JR, Morris PJ Glycosuria: an index of cyclosporine nephrotoxicity. Transplant Proc 1987, 19:1780. (1 Pt 2).
61. Chapman JR, Griffiths D, Harding NG, et al. Reversibility of cyclosporin nephrotoxicity after three months' treatment. Lancet 1985, 1:128-130.
62. Chapman JR, Thompson JF, Wood RFL, et al. The problems associated with conversion to cyclosporin immunosuppression in long-term renal allograft recipients. Transplant Proc 1985, 17:1178.
63. Cheigh JS, Suthanthiran M, Fotino M, et al. Minimal sensitization and excellent renal allograft outcome following donor-specific blood transfusion with a short course of cyclosporine. Transplantation 1991, 51:378-381.
64. Chen T, Guo J, Yang M, et al. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 2004, 103:413-421.
65. Chow SS, Thorner P, Baumal R, et al. Cyclosporine and experimental renal ischemic injury. Transplantation 1986, 41:152-156.
66. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993, 55:300-304.
67. Ciesek S, Ringe BP, Strassburg CP, et al. Effects of cyclosporine on human dendritic cell subsets. Transplant Proc 2005, 37:20-24.
68. Citterio F, Pozzetto U, Romagnoli J, et al. Plasma levels of transforming growth factor-beta1 in renal transplant recipients receiving different immunosuppressive regimens. Transplant Proc 2004, 36:698-699.
69. Citterio F, Scata MC, Romagnoli J, et al. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion. Transplantation 2005, 79:802-806.
70. Clipstone NA, Crabtree GR Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357:695-697.
71. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003, 75:2086-2090.
72. Colgan J, Asmal M, Yu B, et al. Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol 2005, 174:6030-6038.
73. Collaborative Transplant Study. Newsletter March 2001, vol 2006, 2001.
74. Coukell AJ, Plosker GL Cyclosporin microemulsion (Neoral): a pharma-coeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Pharmacoeconomics 1998, 14:691-708.
75. Coupes BM, Newstead CG, Short CD, et al. Transforming growth factor beta 1 in renal allograft recipients. Transplantation 1994, 57:1727-1731.
76. Coward RA, Raferty AT, Brown CB Cyclosporin and antituberculous therapy. Lancet 1985, 1:1342-1343.
77. Crocker JF, Dempsey T, Schenk ME, et al. Cyclosporin A toxicity in children. Transplant Rev 1993, 7:72.
78. d'Ardenne AJ, Dunnill MS, Thompson JF, et al. Cyclosporin and renal graft histology. J Clin Pathol 1986, 39:145-151.
79. Daneshmend TK Ketoconazole-cyclosporin interaction. Lancet 1982, 2:1342-1343.
80. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628.
81. David-Neto E, Kakehashi E, Alves CF, et al. Bioequivalence of a new cyclosporine A formulation to Neoral. Ther Drug Monit 2004, 26:53-57.
82. Dawidson I, Rooth P Improvement of cadaver renal transplantation outcomes with verapamil: a review. Am J Med 1991, 90(Suppl 5A):37S-41S.
83. De Vecchi A, Tarantino A, Rivotta E, et al. Need for steroids in cyclosporin (Cy) treated cadaveric renal transplant recipients (pts). Kidney Int 1985, 28:394.
84. de Vries AP, Oterdoom LH, Gans RO, et al. Supplementation with anti-oxidants vitamin C and E decreases cyclosporine A trough-levels in renal transplant recipients. Nephrol Dial Transplant 2006, 21:231-232.
85. Deierhoi MH, Sollinger HW, Kalayoglu M, et al. Quadruple therapy for cadaver renal transplantation. Transplant Proc 1987, 19:1917-1919. (1 Pt 3).
86. Deray G, Le Hoang P, Achour L, et al. Cyclosporin and Raynaud phenomenon. Lancet 1986, 2:1092-1093.
87. Dominguez J, Kompatzki A, Foradori A, et al. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Transplant Proc 2003, 35:2522-2523.
88. Dreyfuss M, Harri E, Hoftmann H, et al. Cyclopsorin A and C: new metabolites from Trichoderma polysporum. Eur J Appl Microbiol 1976, 3:125.
89. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005, 79:466-475.
90. El-Agroudy AE, Sobh MA, Hamdy AF, et al. A prospective, randomized study of coadministration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation 2004, 77(9 Suppl):1371-1376.
91. Ferguson RM, Rynasiewicz JJ, Sutherland DE, et al. Cyclosporin A in renal transplantation: a prospective randomized trial. Surgery 1982, 92:175-182.
92. Ferguson RM, Sutherland DE, Simmons RL, et al. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet 1982, 2:882-883.
93. Ferguson RM A multicentre experience with sequential ALG/cyclosporine therapy in renal transplantation. Clin Transplant 1988, 2:285.
94. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction: long-term follow-up and preliminary results of a randomized trial. Transplantation 1993, 55:1000-1004.
95. Fischer G, Wittmann-Liebold B, Lang K, et al. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337:476-478.
96. Fischer G, Schmid FX The mechanism of protein folding: implications of in vitro refolding models for de novo protein folding and translocation in the cell. Biochemistry 1990, 29:2205-2212.
97. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991, 352:803-807.
98. Flechner SM, Kerman RH, van Burren C, et al. The using of cyclosporin and prednisolone for high MLC haploidentical living related renal transplantation. Transplant Proc 1983, 15:442.
99. Flechner SM, Payne WD, Van Buren C, et al. The effect of cyclosporine on early graft function in human renal transplantation. Transplantation 1983, 36:268-272.
100. Flechner SM, Kerman RH, Van Buren CT, et al. Does cyclosporine improve the results of HLA-identical renal transplantation?. Transplant Proc 1987, 19:1485-1488. (1 Pt 2).
101. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004, 4:1776-1785.
102. Foley RJ, Hamner RW, Weinman EJ Serum potassium concentrations in cyclosporine- and azathioprine-treated renal transplant patients. Nephron 1985, 40:280-285.
103. French ME, Thompson JF, Hunniset AG, et al. Impaired function of renal allografts during treatment with cyclosporin A nephroxicity or rejection. Transplant Proc 1983, 15:485.
104. Friedman J, Weissman I Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell 1991, 66:799-806.
105. Fries D, Kechrid C, Charpentier B, et al. A prospective study of a triple association: cyclosporin, corticosteroids and azathioprine in immunologically high risk renal transplantation. Transplant Proc 1985, 17:1213.
106. Fries D, Hiesse C, Charpentier B, et al. Triple combination of low-dose cyclosporine, azathioprine, and steroids in first cadaver donor renal allografts. Transplant Proc 1987, 19:1911-1914. (1 Pt 3).
107. Fuggle SV, McWhinnie DL, Chapman JR, et al. Sequential analysis of HLA-class II antigen expression in human renal allografts: induction of tubular class II antigens and correlation with clinical parameters. Transplantation 1986, 42:144-150.
108. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004, 78:1653-1660.
109. Gallego MJ, Garcia Villalon AL, Lopez Farre AJ, et al. Mechanisms of the endothelial toxicity of cyclosporin A: role of nitric oxide, cGMP, and Ca2+. Circ Res 1994, 74:477-484.
110. Gardiner DS, Watson MA, Junor BJ, et al. The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies. Nephrol Dial Transplant 1991, 6:363-367.
111. Gaspari F, Anedda MF, Signorini O, et al. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997, 8:647-652.
112. Gerntholtz T, Pascoe MD, Botha JF, et al. The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries. Eur J Clin Pharmacol 2004, 60(3):143-148.
113. Ghiggeri GM, Altieri P, Oleggini R, et al. Cyclosporine enhances the synthesis of selected extracellular matrix proteins by renal cells "in culture": different cell responses and phenotype characterization. Transplantation 1994, 57:1382-1388.
114. Gill IS, Hodge EE, Novick AC, et al. Azathioprine vs cyclosporine in recipients of HLA-identical renal allografts. Cleve Clin J Med 1994, 61:206-210.
115. Gluckman E, Devergie A, Poirier O, et al. Use of cyclosporine as prophylaxis of graft-vs.-host disease after human allogeneic bone marrow transplantation: report of 38 patients. Transplant Proc 1983, 15(4 Suppl 1-2):2628-2633.
116. Goel M, Flechner SM, Ischikawa A, et al. The effect of two different cyclosporine formulations on the long-term progression to chronic rejection in renal allograft recipients. Clin Transplant 2002, 16:442-449.
117. Gordon MY, Singer JW Selective effects of cyclosporin A on colony-forming lymphoid and myeloid cells in man. Nature 1979, 279:433-434.
118. Granelli-Piperno A In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med 1988, 168:1649-1658.
119. Granelli-Piperno A, Nolan P, Inaba K, et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J Exp Med 1990, 172:1869-1872.
120. Gratwohl A, Forster I, Speck B Skin grafts in rabbits with cyclosporin A: absence of induction of tolerance and untoward side effects. Transplantation 1981, 31:136-138.
121. Green CJ, Allison AC Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment. Lancet 1978, 1:1182-1183.
122. Grevel J, Welsh MS, Kahan BD Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989, 11:246-248.
123. Griffin PJ, Gomes da Costa CA, Salaman JR Renal transplantation without steroids: a controlled clinical trial. Transplant Proc 1986, 18:797.
124. Gross ML, Pearson RM, Kennedy J, et al. Rejection encephalopathy. Lancet 1982, 2:1217.
125. Groth CG There is no need to give blood transfusions as pretreatment for renal transplantation in the cyclosporine era. Transplant Proc 1987, 19:153-154. (1 Pt 1).
126. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999, 67:1036-1042.
127. Groux H, Torpier G, Monte D, et al. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331-340.
128. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
129. Hardie IR, Tiller DJ, Mahony JF, et al. Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee. Transplant Proc 1993, 25:583-584. (1 Pt 1).
130. Hardinger KL, Schnitzler MA, Koch MJ, et al. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. Transplantation 2004, 78:1198-1203.
131. Hariharan S, Kasiske B, Matas A, et al. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004, 4:1179-1183.
132. Haug C, Duell T, Voisard R, et al. Cyclosporine A stimulates endothelin release. J Cardiovasc Pharmacol 1995, 26(Suppl 3):S239-S241.
133. Hayry P, Ahonen J, von Willebrand E, et al. Discontinuation of one drug in triple-drug immunosuppression with cyclosporine, azathioprine, and steroids: an interim report. Transplant Proc 1988, 20:449-450.
134. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005, 16:2509-2516.
135. Heaf JG, Sprague SM, Josephson MA Bone disease after renal transplantation. Transplantation 2003, 75:315-325.
136. Hedley D, Powles RL, Morgenstein GR Toxicity of cyclosporin A in patients following bone marrow transplantation. Cyclosporine A 1982, 545. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
137. Henriksen I, Hansen BL, Birkeland SA Conversion of long-term renal allograft recipients from prednisolone/azathioprine to cyclosporin. Transplant Proc 1986, 18:1002.
138. Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001, 137:14-20.
139. Hess AD, Tutschka PJ Effect of cyclosporin A on human lymphocyte responses in vitro, I: CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol 1980, 124:2601-2608.
140. Hess AD, Tutschka PJ, Santos GW The effect of cyclosporin A on T-lymphocyte subpopulations. Cyclosporine A 1982, 209. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
141. Hess AD, Tutschka PJ, Santos GW Effect of cyclosporin A on human lymphocyte responses in vitro, III: CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982, 128:355-359.
142. Hess AD, Bright EC Cyclosporine inhibits T-cell activation at two distinct levels: role of the CD 28 activation pathway. Transplant Proc 1991, 23:961-966. (1 Pt 2).
143. Hibberd AD, Trevillian PR, Roger SD, et al. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. Transplantation 2006, 81:711-717.
144. Higgins RM, Hart P, Lam FT, et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. Transplantation 2000, 69:1736-1739.
145. Hillebrand G, Castro JA, Habersetzer R Chronic cyclosporin hepatotoxicity after renal transplantation. Transplant Proc 1986, 18:1020.
146. Hillis AN, Duguid J, Evans CM, et al. Three year experience of donor specific transfusion and concomitant cyclosporine A. Transplant Proc 1987, 19:2248-2249. (1 Pt 3).
147. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
148. Holt DW, Marsden JT, Johnston A, et al. Blood cyclosporin concentrations and renal allograft dysfunction. BMJ (Clin Res Ed) 1986, 293:1057-1059.
149. Homan WP, Fabre JW, Millard PR, et al. Effect of cyclosporin A upon second-set rejection of rat renal allografts. Transplantation 1980, 30:354-357.
150. Homan WP, Fabre JW, Williams KA, et al. Studies on the immunosuppressive properties of cyclosporin A in rats receiving renal allografts. Transplantation 1980, 29:361-366.
151. Homan WP, French ME, Morris PJ Effect of cyclosporin A upon the function of ischemically damaged renal autografts in the dog. Transplantation 1980, 30:228-230.
152. Horsburgh T, Wood P, Brent L Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes. Nature 1980, 286:609-611.
153. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374-377.
154. Huber S, Schramm C, Lehr HA, et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004, 173:6526-6531.
155. Illner WD, Land W, Habersetzen R Cyclosporine in combination with azathioprine and steroids in cadaveric renal transplantation. Transplant Proc 1985, 17:181.
156. International Neoral Renal Transplantation Study Group Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002, 2:148-156.
157. Islam M, Burke JF, McGowan TA, et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001, 59:498-506.
158. Jablonski P, Harrison C, Howden B, et al. Cyclosporine and the ischemic rat kidney. Transplantation 1986, 41:147-151.
159. Johnson DW, Saunders HJ, Johnson FJ, et al. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther 1999, 289:535-542.
160. Johnson RWG, Wise MH, Bukran A A four-year prospective study of cyclosporin in cadaveric renal transplantation. Transplant Proc 1985, 17:1197.
161. Johnston A, Holt DW Immunosuppressant drugs-the role of therapeutic drug monitoring. Br J Clin Pharmacol 2001, 52(Suppl 1):61S-73S.
162. Johnston A, Belitsky P, Frei U, et al. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Pharmacol 2004, 60:389-395.
163. Jones RM, Murie JA, Allen RD, et al. Triple therapy in cadaver renal transplantation. Br J Surg 1988, 75:4-8.
164. Jones RM, Murie JA, Ting A, et al. Renal vascular thrombosis of cadaveric renal allografts in patients receiving cyclosporine, azathioprine and prednisolone triple therapy. Clin Transplant 1988, 2:122.
165. Joss N, Rodger RS, McMillan MA, et al. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data. Transplantation 2007, 83:582-587.
166. Julien J, Farge D, Kreft-Jais C, et al. Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation 1993, 56:885-891.
167. June CH, Thompson CB, Kennedy MS, et al. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation 1985, 39:620-624.
168. Kahan BD, Kerman R, Agostino G, et al. The action of cyclosporin A on human lymphocytes. Cyclosporine A 1982, 281. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
169. Kahan BD Donor specific transfusions-a balanced view. Prog Transplant 1984, 1:115.
170. Kahan BD Cyclosporine. N Engl J Med 1989, 321:1725-1738.
171. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996, 62:599-606.
172. Kamar N, Garrigue V, Karras A, et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 2006, 6:1042-1048. (5 Pt 1).
173. Kanazi G, Stowe N, Steinmuller D, et al. Effect of cyclosporine upon the function of ischemically damaged kidneys in the rat. Transplantation 1986, 41:782-784.
174. Kasiske BL, Heim DK, Ma JZ Elective cyclosporine withdrawal after renal transplantation: A meta-analysis. JAMA 1993, 269:395-400.
175. Keevil BG, Tierney DP, Cooper DP, et al. Rapid liquid chromatography-tandem mass spectrometry method for routine analysis of cyclosporin A over an extended concentration range. Clin Chem 2002, 48:69-76.
176. Kehrl JH, Grove JH, Goldsmith PK, et al. B cell growth and differentiation factors interact with receptors distinct from the interleukin 2 receptor. Eur J Immunol 1986, 16:761-766.
177. Keown P (on behalf of the Canadian Neoral Study Group) Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001, 72:1024-1032.
178. Keown PA, Essery GL, Stiller CR, et al. Mechanisms of immunosuppression by cyclosporin. Transplant Proc 1981, 13:386-389. (1 Pt 1).
179. Keown PA, Stiller CR, Ulan RA, et al. Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet 1981, 1:686-689.
180. Keown PA, Essery-Rice G, Hellstrom A, et al. Inhibition of human in vivo cytotoxic T lymphocyte generation by cyclosporine following organ transplantation. Transplantation 1985, 40:45-49.
181. Keusch G, Baumgartner D, Gmur NJ, et al. Erythrocytosis (E) after kidney allotransplantation (KT): hematological characterization and complications. Kidney Int 1985, 28:377.
182. Khanna A, Li B, Sehajpal PK, et al. Mechanism of action of cyclosporine: a new hypothesis implicating transforming growth factor-β. Transplant Rev 1995, 9:41.
183. Khanna AK, Cairns VR, Becker CG, et al. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999, 67:882-889.
184. Klaus CG, Dongworth DW Effects of cyclosporin A on B cell functions in the mouse. Cyclosporine A 1982, 233. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
185. Klintmalm GB, Iwatsuki S, Starzl TE Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981, 32:488-489.
186. Knight SR, Morris PJ The clinical benefits of cyclosporine C2-level monitoring: A systematic review. Transplantation 2007, 83:1525-1535.
187. Koller-Strametz J, Wolzt M, Fuchs C, et al. Renal hemodynamic effects of L-arginine and sodium nitroprusside in heart transplant recipients. Kidney Int 1999, 55:1871-1877.
188. Kostakis AJ, White DJ, Calne RY Prolongation of rat heart allograft survival by cyclosporin. IRCSJ Med Sci 1977, 5:280.
189. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 1994, 58:658-663.
190. Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
191. Kovarik JM, Koelle EU Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999, 15:197-205.
192. Kreis H, Chkoff N, Chatenoud L, et al. A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejection. Transplant Proc 1989, 21:1741-1744. (1 Pt 2).
193. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000, 69:1252-1260.
194. Kunkle A, Klaus GGB Selective effects of cyclosporin A on functional B cell subsets in the mouse. J Immunol 1980, 125:2526.
195. Kyllonen LE, Salmela KT Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. Transplantation 2006, 81:1010-1015.
196. Lafferty KJ, Borel JF, Hodgkin P Cyclosporin A (CSA): models for the mechanism of action. Transplant Proc 1983, 15:2242.
197. Lanese DM, Conger JD Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993, 91:2144-2149.
198. Larsson EL Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 1980, 124:2828-2833.
199. Lassila M Interaction of cyclosporine A and the renin-angiotensin system: new perspectives. Curr Drug Metab 2002, 3:61-71.
200. Leapman SB, Filo RS, Smith EJ, et al. Differential effects of cyclosporin-A on lymphocyte subpopulations. Transplant Proc 1981, 13:405-409. (1 Pt 1).
201. Lee DB Cyclosporine and the renin-angiotensin axis. Kidney Int 1997, 52:248-260.
202. Lee JI, Ganster RW, Geller DA, et al. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 1999, 68:1255-1263.
203. Letizia C, De Biase L, Caliumi C, et al. Endothelin-1 circulating levels increase in patients with orthotopic heart transplantation and in chronic therapy with cyclosporine. Minerva Cardioangiol 2001, 49:15-22.
204. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002, 73(9 Suppl):S12-S18.
205. Li C, Lim SW, Sun BK, et al. Chronic cyclosporine nephrotoxicity: new insights and preventive strategies. Yonsei Med J 2004, 45:1004-1016.
206. Lin HL, Lui WY, Liu TY, et al. Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer 2003, 88:973-980.
207. Lindholm A, Dahlqvist R, Groth GG, et al. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 1990, 30:443-452.
208. Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003, 14:377-388.
209. Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
210. MacDonald AS, Daloze P, Dandavino R, et al. A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Canadian Transplant Group. Transplant Proc 1987, 19:1865-1866. (1 Pt 3).
211. Macdonald P, Keogh A, Connell J, et al. Diltiazem co-administration reduces cyclosporine toxicity after heart transplantation: a prospective randomised study. Transplant Proc 1992, 24:2259-2262.
212. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999, 68:55-62.
213. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001, 12:828-833.
214. Maham N, Cardella C, Cattran D, et al. Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience. Transplant Proc 2001, 33(7-8):3098-3099.
215. Malyszko J, Malyszko JS, Pawlak K, et al. The coagulolytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation 1996, 62:828-830.
216. Mangal AK, Growe GH, Sinclair M, et al. Acquired hemolytic anemia due to "auto"-anti-A or "auto"-anti-B induced by group O homograft in renal transplant recipients. Transfusion 1984, 24:201-205.
217. Martin JE, Daoud AJ, Schroeder TJ, et al. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999, 15:317-337.
218. Masri MA, Haberal M, Rizvi A, et al. The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study. Transplant Proc 2004, 36:80-83.
219. Matl I, Viklicky O, Voska L, et al. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients. Transpl Int 2005, 18:668-671.
220. Matsue H, Yang C, Matsue K, et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002, 169:3555-3564.
221. Mattila PS, Ullman KS, Fiering S, et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J 1990, 9:4425-4433.
222. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001, 71:900-905.
223. Merion RM, Calne RY Allograft renal vein thrombosis. Transplant Proc 1985, 17:1746-1750.
224. Milton AD, Spencer SC, Fabre JW The effects of cyclosporine on the induction of donor class I and class II MHC antigens in heart and kidney allografts in the rat. Transplantation 1986, 42:337-347.
225. Montagnino G, Tarantino A, Banfi G, et al. A randomized trial comparing triple-drug and double-drug therapy in renal transplantation: analysis at 7 years. Transplantation 1994, 58:149-154.
226. Morris PJ Cyclosporin A. Transplantation 1981, 32:349-354.
227. Morris PJ, French ME, Dunnill MS, et al. A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983, 36:273-277.
228. Morris PJ, Mason DW, Hutchinson IV The effect of cyclosporin A on lymphocytes in animal models of tissue transplantation. Transplant Proc 1983, 15:2287.
229. Morris PJ, Chapman JR, Allen RD, et al. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1987, 1:586-591.
230. Morris PJ, Russell NK Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006, 81:1361-1367.
231. Morris ST, McMurray JJ, Rodger RS, et al. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000, 57:1100-1106.
232. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005, 5:1748-1756.
233. Murray BM, Paller MS, Ferris TF Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985, 28:767-774.
234. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984, 311:699-705.
235. Najarian JS, Ferguson RM, Sutherland DE, et al. A prospective trial of the efficacy of cyclosporin in renal transplantation at the University of Minnesota. Transplant Proc 1983, 15:438.
236. Najarian JS, Fryd DS, Strand M, et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985, 201:142-157.
237. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997, 350:1193-1198.
238. Navarro-Antolin J, Rey-Campos J, Lamas S Transcriptional induction of endothelial nitric oxide gene by cyclosporine A: a role for activator protein-1. J Biol Chem 2000, 275:3075-3080.
239. Neild GH, Taube DH, Hartley RB, et al. Morphological differentiation between rejection and cyclosporin nephrotoxicity in renal allografts. J Clin Pathol 1986, 39:152-159.
240. Nitta K, Friedman AL, Nicastri AD, et al. Granular juxtaglomerular cell hyperplasia caused by cyclosporine. Transplantation 1987, 44:417-421.
241. Norman DJ, Kahana L, Stuart FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993, 55:44-50.
242. Nyberg G, Sandberg L, Rydberg L, et al. ABO-autoimmune hemolytic anemia in a renal transplant patient treated with cyclosporine: a case report. Transplantation 1984, 37:529-530.
243. Nyberg G, Haljamae U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation 1998, 65:253-255.
244. O'Garra A, Warren DJ, Holman M, et al. Effects of cyclosporine on responses of murine B cells to T cell-derived lymphokines. J Immunol 1986, 137:2220-2224.
245. O'Keefe SJ, Tamura J, Kincaid RL, et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992, 357:692-694.
246. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005, 18:22-28.
247. Oberholzer J, Thielke J, Hatipoglu B, et al. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc 2005, 37:999-1000.
248. Olshan AF, Mattison DR, Zwanenburg TS, International Commission for Protection Against Environmental Mutagens and Carcinogens Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosporine A, August 18, 1993. Mutat Res 1994, 317:163-173.
249. Opelz G Multicenter impact of ciclosporin on cadaver kidney graft survival. Prog Allergy 1986, 38:329-345.
250. Opelz G, Wujciak T, Dohler B, et al. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999, 1:334-342.
251. Opelz G, Dohler B Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4:222-230.
252. Ost L, Lundgren G, Groth CG Renal transplants in the older patients. Prog Transplant 1985, 2:1.
253. Oyer PE, Stinson EB, Reitz BA Preliminary results with cyclosporin A in clinical cardiac transplantation. Cyclosporine A 1982, 461. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
254. Ozdemir BH, Ozdemir FN, Demirhan B, et al. TGF-beta1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 2005, 80:1681-1685.
255. Paavonen T, Hayry P Effect of cyclosporin A on T-dependent and T-independent immunoglobulin synthesis in vitro. Nature 1980, 287:542-544.
256. Palacios R, Moller G Cyclosporin A blocks receptors for HLA-DR antigens on T cells. Nature 1981, 290:792-794.
257. Palestine AG, Austin HA, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986, 314:1293-1298.
258. Pankewycz OG, Miao L, Isaacs R, et al. Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity. Kidney Int 1996, 50:1634-1640.
259. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003, 75:1501-1505.
260. Perico N, Dadan J, Remuzzi G Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990, 1:76-83.
261. Perico N, Remuzzi G Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplant Rev 1991, 5:63.
262. Pescovitz MD, Barbeito R Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002, 16:378-382.
263. Pflugii G, Kallen J, Schirmer T, et al. X-ray structure of decameric cyclosporin-cyclosporin crystal complex. Nature 1993, 361:91.
264. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995, 6:1186-1196.
265. Pisetsky DS, Haughton G Cyclosporine inhibition of a murine B cell lymphoma. Clin Exp Immunol 1986, 63:549-554.
266. Ponticelli C, Minetti L, Di Palo FQ, et al. The Milan clinical trial with cyclosporine in cadaveric renal transplantation: a three-year follow-up. Transplantation 1988, 45:908-913.
267. Ponticelli C Generic cyclosporine: a word of caution. J Nephrol 2004, 17(Suppl 8):S20-S24.
268. Praditpornsilpa K, Avihingsanon Y, Nivatvong S, et al. Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation. Clin Transplant 2005, 19:335-339.
269. Qazi YA, Forrest A, Tornatore K, et al. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 2006, 20:313-317.
270. Ramsey G, Nusbacher J, Starzl TE, et al. Isohemagglutinins of graft origin after ABO-unmatched liver transplantation. N Engl J Med 1984, 311:1167-1170.
271. Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996, 348:643-648.
272. Remuzzi G, Bertani T Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989, 13:261-272.
273. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503-512.
274. Renders L, Mayer-Kadner I, Koch C, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001, 16:141-146.
275. Rigotti P, Flechner SM, Van Buren CT, et al. Increased incidence of renal allograft thrombosis under cyclosporine immunosuppression. Int Surg 1986, 71:38-41.
276. Roby KA, Shaw LM Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol 1993, 4:168-177.
277. Rondeau E, Paillard F, Peraldi MN, et al. Role of the renin-angiotensin system on the renal functional reserve in renal transplant recipients. Kidney Int 1993, 44:165-172.
278. Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002, 74:1013-1017.
279. Saint-Marcoux F, Rousseau A, Le Meur Y, et al. Influence of samplingtime error on cyclosporine measurements nominally at 2 hours after administration. Clin Chem 2003, 49:813-815.
280. Salaman JR, Griffin PJ Fine-needle intrarenal manometry: a new test for rejection in cyclosporin-treated recipients of kidney transplants. Lancet 1983, 2:709-711.
281. Salaman JR, Griffin PJA Fine needle intrarenal manometry in the management of renal transplant patients receiving cyclosporin. Transplant Proc 1985, 17:1275.
282. Salomon DR An alternative view minimizing the significance of cyclosporine nephrotoxicity and in favor of enhanced immunosup-pression for long-term kidney transplant recipients. Transplant Proc 1991, 23:2115-2118.
283. Salomon DR Cyclosporine nephrotoxicity and long-term renal transplantation. Transplant Rev 1992, 6:10.
284. Salvatierra O Donor-specific transfusions in living-related transplantation. World J Surg 1986, 10:361-368.
285. Santana A, Guerra J, Milhomens C, et al. C0/C2 cyclosporine levels monitoring in renal transplantation. Transplant Proc 2003, 35:1072-1073.
286. Savoldi S, Sandrini S, Scolari F, et al. Is cyclosporine administration in twice daily dose advantageous?. Transplant Proc 1987, 19:1720-1722. (1 Pt 2).
287. Schmidt U, Mihatsch MJ, Albert FW Morphologic findings of kidney transplants one year after treatment with cyclosporin A (CyA) alone or in combination with low dose steroids. Transplant Proc 1986, 18:1266.
288. Schnuelle P, Van DHJH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002, 13:536-543.
289. Schreiber SL, Crabtree GR The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136-142.
290. Schreier MH, Baumann G, Zenke G Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties?. Transplant Proc 1993, 25:502-507. (1 Pt 1).
291. Schroeder TJ, Hariharan S, First MR Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994, 26:2787-2790.
292. Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation-data on four cases and review of the literature. Transplantation 1993, 55:95-103.
293. Seymour RA, Jacobs DJ Cyclosporin and the gingival tissues. J Clin Periodontol 1992, 19:1-11.
294. Shah MB, Martin JE, Schroeder TJ, et al. The evaluation of the safety and tolerability of two formulations of cyclosporine: Neoral and Sandimmune: a meta-analysis. Transplantation 1999, 67:1411-1417.
295. Shah S, Collett D, Johnson R, et al. Long-term graft outcome with mycophenolate mofetil and azathioprine: a paired kidney analysis. Transplantation 2006, 82:1634-1639.
296. Sharma A, Shekhar C, Heer M, et al. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. Transplant Proc 2006, 38:2051-2053.
297. Sheil AG, Hall BM, Tiller DJ Australian trial of cyclosporine (Csa) in cadaveric donor renal transplantation. Transplant Proc 1983, 15:2845.
298. Sheild CF, Hughes JD, Lemon JA Prophylactic OKT3 and cadaveric renal transplantation at a single centre. Clin Transplant 1988, 2:190.
299. Shihab FS, Andoh TF, Tanner AM, et al. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis 1997, 30:71-81.
300. Shihab FS, Bennett WM, Tanner AM, et al. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997, 52:660-673.
301. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003, 63:522-533.
302. Sigal NH, Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992, 10:519-560.
303. Simmons RL, Canafax DM, Fryd DS, et al. New immunosuppressive drug combinations for mismatched related and cadaveric renal transplantation. Transplant Proc 1986, 18(2 Suppl 1):76-81.
304. Sinclair NR Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. Can Med Assoc J 1992, 147:645-657.
305. Sitland T, Kiberd B, Lawen J, et al. Conversion of long term, Neoral treated kidney transplant recipients from C0 to C2 monitoring: 6 month follow-up. Am J Transplant 2002, 2(Suppl 3):232.
306. Slapak M, Geoghegan T, Digard N The use of low dose cyclosporin in combination with azathioprine and steroids in renal transplantation. Transplant Proc 1985, 17:1222.
307. Smak GPJH, De SRGL, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002, 13:1365-1373.
308. Sodal G, Albrechtsen D, Berg KJ, et al. Renal transplantation from living donors mismatched for two HLA haplotypes. Transplant Proc 1987, 19:1509-1510. (1 Pt 2).
309. Sollinger HW Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225-232.
310. Somner BG, Henry ML, Ferguson RM Obliterative renal arteriopathy following cyclosporine therapy. Transplant Proc 1986, 18(Suppl 1):1285.
311. Sprague SM, Josephson MA Bone disease after kidney transplantation. Semin Nephrol 2004, 24:82-90.
312. Squifflet JR, Sutherland DER, Field J Synergistic immunosuppressive effect of cyclosporin A and azathioprine. Transplant Proc 1983, 15:520.
313. Starzl TE, Kakala TR, Iwatsuki S Cyclosporin A and steroid treatment in 104 cadaveric renal transplantation. Cyclosporine A 1982, 363. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
314. Starzl TE, Kakala TR, Rosenthal JT, et al. The Colorado-Pittsburg cadaveric renal transplantation study with cyclosporin. Transplant Proc 1983, 15:2459.
315. Steimer W Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?. Clin Chem 1999, 45:371-381.
316. Stiller C The requirements for maintenance steroids in cyclosporin-treated renal transplant recipients. Transplant Proc 1983, 15(Suppl 1):2490.
317. Streblow DN, Kitabwalla M, Malkovsky M, et al. Cyclophilin A modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology 1998, 245:197-202.
318. Stroes ES, Luscher TF, de Groot FG, et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997, 29:570-575.
319. Sumrani N, Delaney V, Ding ZK, et al. HLA-identical renal transplants: impact of cyclosporine on intermediate-term survival and renal function. Am J Kidney Dis 1990, 16:417-422.
320. Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes?. Transplantation 2005, 80:1633-1635.
321. Tajima K, Amakawa R, Ito T, et al. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003, 108:321-328.
322. Takahashi N, Hayano T, Suzuki M Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989, 337:473-475.
323. Tanner JE, Menezes J Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease. Blood 1994, 84:3956-3964.
324. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991, 52:53-57.
325. Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995, 333:333-336.
326. Theil G, Loertscher R, Brunner FB Conversion from conventional immunosuppression to cyclosporin A therapy in diabetic recipients of cadaveric kidney transplants. Transplant Proc 1984, 16:640.
327. Theriault Y, Logan TM, Meadows R, et al. Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature 1993, 361:88-91.
328. Thiru S, Calne RY, Nagington J Lymphoma in renal allograft patients treated with cyclosporin-A as one of the immunosuppressive agents. Transplant Proc 1981, 13:359-364. (1 Pt 1).
329. Thompson CB, June CH, Sullivan KM, et al. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984, 2:1116-1120.
330. Thompson JF, Chalmers DH, Carter NP, et al. Clinical and immunologic effects of conversion to cyclosporin-A therapy in long-term renal allograft recipients. Transplant Proc 1983, 15:1930.
331. Thomson AW, Whiting PH, Simpson JG Pathobiology of cyclosporin A in experimental animals. Cyclosporine A 1982, 177. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
332. Tiemessen MM, Kunzmann S, Schmidt-Weber CB, et al. Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. Int Immunol 2003, 15:1495-1504.
333. Tutschka PJ, Hess AD, Beschorner WE, et al. Cyclosporin A in allogenic bone marrow transplantation: preclinical and clinical studies. Cyclosporine A 1982, 519. Elsevier Biomedical Press, Amsterdam. D.J. White (Ed.).
334. Twentyman PR, Fox NE, White DJ Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987, 56:55-57.
335. Umlauf SW, Beverly B, Kang SM, et al. Molecular regulation of the IL-2 gene: rheostatic control of the immune system. Immunol Rev 1993, 133:177-197.
336. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985, 1:999-1002.
337. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005, 80:765-774.
338. Velez RL, Brinker KR, Vergne-Marini PJ, et al. Renal transplantation with cyclosporine in the elderly population. Transplant Proc 1991, 23:1749-1752.
339. Venkataraman L, Francis DA, Wang Z, et al. Cyclosporin-A sensitive induction of NF-AT in murine B cells. Immunity 1994, 1:189-196.
340. Videla C, Vega J, Borja H Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adult renal recipients receiving ketoconazole. Transplant Proc 2005, 37:1574-1576.
341. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338:161-165.
342. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004, 10:939-944.
343. Waiser J, Dell K, Bohler T, et al. Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. Nephrol Dial Transplant 2002, 17:1568-1577.
344. Wallick SC, Figari IS, Morris RE, et al. Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med 1990, 172:1777-1784.
345. Walz G, Zanker B, Melton LB, et al. Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine. Transplantation 1990, 49:191-194.
346. Wamboldt FW, Weiler SJ, Kalin NH Cyclosporin-associated mania. Biol Psychiatry 1984, 19:1161-1162.
347. Wang K, Zhang H, Li Y, et al. Efficacy of mycophenolate mofetil versus azathioprine after renal transplantation: a systematic review. Transplant Proc 2004, 36:2071-2072.
348. Wang XH, Xu D: Using neoral C2 monitoring as the predictor in the de novo renal transplant recipients-a prospective one year study. XIXth International Congress of the Transplantation Society, Miami, Fla, Aug 25-30, 2002 (abstract).
349. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38:1282-1288.
350. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005, 19:111-122.
351. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005, 5:2496-2503.
352. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331:810.
353. White DJ, Plumb AM, Pawelec G, et al. Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells. Transplantation 1979, 27:55-58.
354. Whiting PH, Simpson JG, Davidson RJ, et al. The toxic effects of combined administration of cyclosporin A and gentamicin. Br J Exp Pathol 1982, 63:554-561.
355. Whiting PH, Thomson AW, Blair JT, et al. Experimental cyclosporin A nephrotoxicity. Br J Exp Pathol 1982, 63:88-94.
356. Wicker LS, Boltz RC, Matt V, et al. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 1990, 20:2277-2283.
357. Wiesinger D, Borel JF Studies on the mechanism of action of cyclosporin A. Immunobiology 1980, 156(4-5):454-463.
358. Yale JF, Roy RD, Grose M, et al. Effects of cyclosporine on glucose tolerance in the rat. Diabetes 1985, 34:1309-1313.
359. Yang CW, Kim YS, Kim J, et al. Oral supplementation of L-arginine prevents chronic cyclosporine nephrotoxicity in rats. Exp Nephrol 1998, 6:50-56.
360. Yang CW, Ahn HJ, Kim WY, et al. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 2003, 75:309-315.
361. Zakliczynski M, Krynicka A, Szewczyk M, et al. Limited utility of cyclosporine C2 monitoring in heart transplant recipients receiving ketoconazole. Transplant Proc 2003, 35:2333-2334.